Core Viewpoint - CICC maintains a target price of HKD 8.9 for China Biologic Products (01177) and a "outperform industry" rating, with adjusted net profit forecasts for 2025 and 2026 remaining at RMB 4.47 billion and RMB 4.92 billion respectively, and introducing a forecast of RMB 5.42 billion for 2027 [1] Group 1 - The company announced a 100% acquisition of Hejia Bio for RMB 1.2 billion [1] - Hejia Bio focuses on the siRNA sector, particularly in the areas of weight loss metabolism, cardiovascular, and neurological diseases, with a core platform that has competitive advantages [1] - The existing therapies in the chronic disease field generally have limitations in efficacy, safety risks, and low patient compliance, indicating a significant unmet clinical need [1] Group 2 - The acquisition is expected to help China Biologic Products build a next-generation cardiovascular treatment innovation pipeline and enhance its layout in the weight loss metabolism field [1] - The company's established R&D system and sales channels are likely to facilitate the efficient clinical advancement and subsequent commercialization of Hejia Bio's products, leading to potential synergistic benefits for both parties [1]

Core Insights - The Hong Kong stock market has seen a strong start in 2026, with eight companies completing their IPOs within just six trading days, including notable firms in the GPU, surgical robotics, and biotechnology sectors [2][3][5] - The initial public offerings (IPOs) have been well-received, with first-day price increases ranging from 8.44% to 109.09%, indicating strong market enthusiasm for sectors like large models, domestic chip alternatives, and surgical robotics [2][3][5] IPO Performance - MiniMax, a key player in the large model sector, achieved a remarkable first-day closing price increase of 109.09%, with a market capitalization reaching HKD 106.7 billion, and was oversubscribed by 1,836.17 times in public offerings [3][5] - Wallen Technology, the first GPU stock in Hong Kong, also performed impressively with a first-day increase of 75.82% [4] - The average first-day increase for the new batch of IPOs was 40.16%, with a cumulative average increase of nearly 62% since listing, reflecting strong market recognition of high-quality hard tech assets [5][6] Market Dynamics - The current IPO market in Hong Kong is characterized by a large backlog of over 300 companies waiting to list, indicating a robust supply pipeline [6] - In December 2025, 32 companies submitted IPO applications, and 26 companies have done so in January 2026 alone, showcasing sustained enthusiasm for new listings [6] Sector Trends - The successful performance of new IPOs has broken the previous trend of "hot IPOs followed by cold market performance," suggesting that the sectors these companies operate in are gaining market confidence [5][6] - Companies like MiniMax and Zhizhu have shown significant cumulative price increases since their IPOs, with MiniMax achieving a total increase of 141.21% and Zhizhu 79.35% [5][6] Regulatory Environment - The Hong Kong Securities and Futures Commission has emphasized the need for high-quality IPO submissions, responding to concerns about the quality of some recent applications [8] - This regulatory focus aims to shift the IPO market from quantity-driven to quality-driven, which may temporarily slow down the listing process for some companies [8]

Group 1 - The core viewpoint of the article is that Rebio Pharmaceuticals-B (6938.HK) is set to be listed on the Hong Kong Stock Exchange tomorrow, with significant interest shown in pre-listing trading [1] - In dark pool trading today, the stock price surged nearly 40%, reaching HKD 81, indicating strong market demand [1] - Each trading lot consists of 200 shares, allowing investors to potentially earn HKD 4,606 per lot, highlighting the lucrative opportunity for early investors [1] Group 2 - Rebio Pharmaceuticals specializes in the research and development of small nucleic acid drugs, particularly focusing on siRNA therapies, positioning itself as a pioneer in this field since its inception in 2007 [1]

Core Viewpoint - Jiangyin Pharmaceutical is seeking to go public on the Hong Kong Stock Exchange, but the China Securities Regulatory Commission (CSRC) has requested additional compliance information regarding its offshore structure and reverse mergers [1][2]. Group 1: Regulatory Compliance - The CSRC has asked Jiangyin Pharmaceutical to provide detailed explanations regarding the compliance of its offshore structure and reverse investment, including adherence to foreign exchange management, overseas investment, foreign investment, and tax management regulations [2]. - The company must clarify the legality of its domestic operating entity established in Shanghai and its historical equity changes [2]. Group 2: Financial Data and Business Operations - Jiangyin Pharmaceutical is required to disclose the proportion of its financial statements that is attributed to its domestic operating entity, and whether unpaid registered capital could negatively impact its business operations and debt repayment capabilities [2]. - The company must provide a conclusive opinion on whether its business scope and actual operations involve sectors that are restricted or prohibited for foreign investment [2]. Group 3: Company Overview - Jiangyin Pharmaceutical is a global clinical-stage biotechnology company focused on maximizing the clinical and commercial value of siRNA therapies [2]. - The company aims to innovate the current treatment standards for chronic diseases through the development of first-in-class and best-in-class siRNA therapies, supported by a proprietary siRNA technology platform and a global collaboration network [2].

Group 1 - The China Securities Regulatory Commission (CSRC) has requested Jiangyin Pharmaceutical to provide supplementary explanations regarding the compliance of its offshore structure and return acquisition [1] - Jiangyin Pharmaceutical submitted its listing application to the Hong Kong Stock Exchange on September 28, 2025, with Goldman Sachs, Haitong International, and HSBC as joint sponsors [1] - The CSRC has outlined specific areas for Jiangyin Pharmaceutical to clarify, including the regulatory procedures related to foreign exchange management, offshore investment, foreign investment, and tax management [1] Group 2 - Jiangyin Pharmaceutical is a global clinical-stage biotechnology company focused on maximizing the clinical and commercial value of siRNA therapies [2] - The company aims to innovate the current treatment standards for chronic diseases through the development of first-in-class and best-in-class siRNA therapies, supported by three major potential blockbuster product pipelines and a proprietary siRNA technology platform [2] - Jiangyin Pharmaceutical's strategy is built on a global collaboration network to address significant unmet medical needs [2]

Core Viewpoint - The pharmaceutical sector has experienced significant fluctuations, with a prolonged downturn from 2021 to 2024, followed by a substantial recovery in 2025. The Hang Seng Medical Index has doubled from its lowest point but still has room to grow compared to previous highs, while the A-share medical index remains significantly below its historical peak [1][2]. Group 1: Investment Opportunities in the Pharmaceutical Sector - The current market sentiment towards the pharmaceutical sector is cautious, with a need to reassess the understanding of the industry and future prospects [2]. - Four major investment opportunities in the pharmaceutical sector over the next three years have been identified, which may influence future fund allocation strategies [2]. Group 2: Domestic High-Value Consumables - Domestic high-value consumables, particularly in the context of "innovation + going global," show strong growth potential, although market consensus is still lacking [3][9]. - The market capitalization of domestic high-value consumables companies is significantly lower than their international counterparts, indicating substantial growth potential [5][9]. - The characteristics of high-value consumables align well with China's manufacturing strengths, suggesting that the emergence of world-class companies in this sector is likely [9][10]. Group 3: U.S. Biotech Sector - The U.S. biotech sector is experiencing a second upward cycle driven by various intracellular biological technologies achieving clinical validation [14]. - The rise of domestic innovative drugs has created competitive pressure on U.S. biotech firms, but it also opens opportunities for collaboration and integration [14][15]. - The market for intracellular technologies is expected to grow, with significant investment opportunities in U.S. biotech companies [16][19]. Group 4: Domestic Innovative Drugs - The domestic innovative drug sector is entering a golden window of opportunity following deep medical reforms, with strong growth potential anticipated in the coming years [23][24]. - The growth trajectory of domestic innovative drugs mirrors that of the U.S. market in the 1980s, suggesting a potential for a prolonged high-growth cycle [25][27]. - The competitive landscape for domestic innovative drugs is evolving, with a focus on maintaining product quality and performance to succeed in a mature global market [27][29]. Group 5: Overall Pharmaceutical Industry Trends - The overall growth rate of the pharmaceutical industry is expected to accelerate marginally over the next three years, improving the industry’s overall outlook [29][30]. - The anticipated recovery in industry revenue and profit margins is driven by the maturation of previously loss-making innovative drug companies and a reduction in competitive pressures [30][35]. - Despite the positive outlook, the market has yet to fully recognize the potential for recovery, as evidenced by low valuation levels compared to historical averages [33].

Core Insights - Novartis has made significant moves in the siRNA therapy space, with a $200 million upfront payment and potential milestone payments of up to $2 billion for the ARO-SNCA deal with Arrowhead, followed by a deal exceeding $5.2 billion for four siRNA drugs with another company, signaling strong market interest in the small nucleic acid field [1] - The global siRNA therapy market is projected to grow from $2.4 billion in 2024 to $50.3 billion by 2040, with a compound annual growth rate (CAGR) of 20.9% [3] - Jiangyin Pharmaceutical has submitted its IPO application in Hong Kong, attracting attention due to its recent significant financing rounds and partnerships in the siRNA sector [2][4] Company Developments - Jiangyin Pharmaceutical has established a diverse product pipeline, including its core product FXI siRNA (SRSD107) for treating coagulation disorders, and two other significant candidates for heart metabolic diseases and obesity [7][9] - The company has successfully raised funds through multiple financing rounds, with a post-money valuation reaching approximately $253 million after its B2 round [4][6] - Jiangyin's collaboration with CRISPR Therapeutics involves a 50:50 co-development model for FXI siRNA, which includes $25 million in cash and $70 million in equity, along with $800 million in milestone payments [6] Market Trends - The siRNA therapy sector has gained traction among investors, with notable stock price increases for small nucleic acid companies in the U.S. market, such as Alnylam, which saw a peak stock price increase of 105.78% this year [3] - Domestic small nucleic acid drug development is rapidly expanding, with over 300 candidates in the pipeline, second only to the U.S. [4] - The standard treatment for anticoagulation has been traditional "NOAC" drugs, but the potential of siRNA therapies like SRSD107 to reduce bleeding risks presents a significant market opportunity [10] Financial Performance - Jiangyin Pharmaceutical reported a net profit of approximately $3.446 million in the first half of the year, supported by cash flow from business development transactions, despite projected net losses of $30.9 million and $34.2 million for 2023 and 2024, respectively [11] - The company has increased its cash and cash equivalents to $618 million, sufficient to support its R&D investments for the next three years [11]

Core Insights - Novartis has made significant investments in the siRNA field, including a $200 million upfront payment and potential milestone payments of up to $2 billion for the ARO-SNCA therapy, and a subsequent deal with Sihuan Pharmaceutical worth over $5.2 billion, signaling strong market interest in small nucleic acid therapies [1][2] - The global siRNA therapy market is projected to grow from $2.4 billion in 2024 to $50.3 billion by 2040, with a compound annual growth rate (CAGR) of 20.9% [2] - Domestic companies in China are rapidly expanding their siRNA drug pipelines, with over 300 new drugs in development, second only to the U.S. [3] Company Developments - Jiangyin Pharmaceutical has submitted its IPO application to the Hong Kong Stock Exchange, with a post-investment valuation of $253 million following multiple funding rounds [3][5] - The company has established a diverse product pipeline, including its core product FXI siRNA (SRSD107), which targets coagulation factor XI and shows promise in reducing thrombotic events while minimizing bleeding risks [6][8] - Jiangyin's collaboration with CRISPR Therapeutics involves a 50:50 co-development model for FXI siRNA, which includes $25 million in cash and $70 million in equity, along with $800 million in milestone payments [5][6] Financial Performance - Despite projected net losses of approximately $309 million and $342 million for 2023 and 2024, respectively, Jiangyin achieved a net profit of $34.46 million in the first half of the year, supported by cash flow from business development transactions [10] - The company has increased its cash and cash equivalents to $618 million, sufficient to cover nearly three years of R&D investments, and is expected to receive $800 million in milestone payments from CRISPR Therapeutics, enhancing its financial stability [10]

Core Insights - Jingyin Pharmaceutical has submitted its listing application to the Hong Kong Stock Exchange, with Goldman Sachs, Haitong International, and HSBC acting as joint sponsors [1] Company Overview - Jingyin Pharmaceutical is a global clinical-stage biotechnology company focused on maximizing the clinical and commercial value of siRNA therapies. The company aims to develop innovative and best-in-class siRNA therapies to address significant unmet medical needs in chronic disease management [4][5] - The company is advancing three major product pipelines targeting coagulation disorders, cardiovascular metabolic diseases, and obesity, which are based on their substantial market potential and the ability to provide transformative siRNA solutions [5] Market Potential - According to a Frost & Sullivan report, the global siRNA therapy market is projected to reach USD 2.4 billion in 2024 and grow to USD 50.3 billion by 2040, with a compound annual growth rate (CAGR) of 20.9% [4] Product Pipeline - The core product, SRSD107, is a potential first-in-class siRNA drug targeting coagulation factor XI, currently undergoing Phase II multi-center clinical trials in Europe, with plans for additional trials in China and Australia/New Zealand [5] - SRSD216 is a potential best-in-class siRNA targeting Lp(a), currently in Phase IIa trials in China and the United States [5] - SRSD384 is an INHBE-targeted candidate for obesity, with promising preclinical data and active IND application progress [5] Technology Platform - The company has developed a proprietary PEPR platform that enhances the stability and target binding of siRNA, enabling more effective and durable therapies. Research is ongoing to expand the delivery range of siRNA beyond the liver to other tissues such as fat, skeletal muscle, heart, kidneys, and the central nervous system [6] Financial Performance - For the six months ending June 30, 2023, the company reported other income and revenue of approximately RMB 8.81 million, with a net loss of approximately RMB 309.41 million. The projected other income and revenue for the same period in 2024 is RMB 9.79 million, with an expected loss of RMB 341.96 million [6][7]

Core Viewpoint - Sirius Therapeutics-B has submitted a listing application to the Hong Kong Stock Exchange, aiming to leverage its proprietary siRNA technology platform to address unmet medical needs in chronic diseases [1] Company Overview - Sirius Therapeutics-B is a global clinical-stage biotechnology company focused on maximizing the clinical and commercial value of siRNA therapies [1] - The company is backed by a strategic foundation that includes three potential blockbuster product pipelines, a proprietary siRNA technology platform, and a global collaboration network [1] Strategic Goals - The company aims to innovate the current treatment standards for chronic diseases by developing first-in-class and best-in-class siRNA therapies targeting significant unmet medical needs globally [1]